Logo

Rakuten Medical Highlights the Preclinical Results of RM-0256 at JCA 2024

Share this

Rakuten Medical Highlights the Preclinical Results of RM-0256 at JCA 2024

Shots:

  • The abstract title was, ‘PD-L1 photoimmunotherapy kills immunosuppressive myeloid cells to activate local and systemic antitumor immunity’
  • The in vitro study depicted its dual MOA of reducing PD-L1 expressing tumor cells & immunosuppressive cells like TAMs & MDSCs plus systemic immune checkpoint inhibition; in vivo study showed effective tumor growth suppression than anti-PD-L1 Ab alone & saline control in anti-PD-L1 sensitive & resistant mouse tumor models, respectively
  • In vivo studies also showed decreased immunosuppressive tumor microenvironment cells & enhanced CD8+ T cell activation to maintain checkpoint inhibition. RM-0256 was well-tolerated when given repeatedly to cynomolgus monkeys in a GLP toxicity study

Ref: Rakuten | Image: Rakuten

Related News: Alopexx Partners with Bharat Biotech to Co-Develop and Commercialize AV0328 Anti-Microbial Vaccine

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions